ARTICLE
8 May 2021

CAFC Patent Cases, 4/20/21-5/4/21

W
WilmerHale

Contributor

WilmerHale provides legal representation across a comprehensive range of practice areas critical to the success of its clients. With a staunch commitment to public service, the firm is a leader in pro bono representation. WilmerHale is 1,000 lawyers strong with 12 offices in the United States, Europe and Asia.
Judge O'Malley dissented for the reasons given in the Appellee's Motion for Reconsideration.
United States Intellectual Property

Precedential Federal Circuit Opinions

  1. MOJAVE DESERT HOLDINGS, LLC v. CROCS, INC. [ORDER] (2020-1167, 4/21/2021) (Newman, Dyk, O'Malley)*    
    Dyk, J. The Court granted a motion by U.S.A. Dawgs, Inc. and Mojave Desert Holdings, LLC to substitute Mojave as U.S.A. Dawgs's successor-in-interest in its appeal from a USPTO inter partes reexamination decision finding a Crocs design patent patentable. The Court explained: "Where, as here, the requester's right has been transferred together with any liability for past infringement, there is no reason that the requester's right to challenge the Board's decision cannot be effectively transferred.... We hold that ... the requester's right (including its right to appeal) may be transferred at least when it occurs as part of the transfer of the requester's past infringement liability." Judge O'Malley dissented for the reasons given in the Appellee's Motion for Reconsideration.
    * WilmerHale represents Crocs on appeal.
  2. BIO-RAD LABORATORIES, INC. v. ITC  [OPINION] (2020-1785, 4/29/2021) (Taranto, Chen, Stoll)  
    Taranto, J. The Court affirmed a decision of the International Trade Commission ("ITC") that Bio-Rad Laboratories, Inc. ("Bio-Rad") infringed three patents owned by 10X Genomics Inc. ("10X") and that 10X satisfied the domestic industry requirement of 19 U.S.C. § 1337. The Court concluded that substantial evidence supported the ITC's findings. The Court also affirmed the ITC's rejection of Bio-Rad's affirmative defense that it allegedly co-owned the asserted patents. The Court explained: "To accept Bio-Rad's contention after we give the required deference to the Commission's factual (and, in one instance, procedural) rulings would require that we find joint inventorship simply because Drs. Hindson and Saxonov, while at Bio-Rad (or QuantaLife), were working on the overall, known problem—how to tag small DNA segments in microfluidics using droplets—that was the subject of widespread work in the art. We see no sound support for such a conclusion."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More